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ABSTRACT 
Objective:  Methotrexate (MTX) is the gold standard in rheumatoid arthritis treatment; however, its continued use is related to hepatotoxicity. 
Thus, the aim of the present work is to evaluate the protective role of silymarin (SLM) against MTX-induced hepatotoxicity. 
Methods:  Male Wistar rats were treated by gavage for 4 weeks as followed:  Control (saline solution, daily), MTX (900µg/kg, once a week and daily 
with saline solution), SLM (50 mg/kg, daily) and MTX+SLM (MTX 900µg/kg, once a week, SLM 50 mg/kg, daily). 
Results:  MTX rats presented macro-and microscopic changes in the liver that was not counteracted by SLM. SLM was able to prevent the significant 
increase in lipid peroxidation observed in the hepatic tissue of MTX rats. SLM+MTX presented a decrease in the hepatic non-proteic thiols compared 
to control; suggesting SLM favors detoxification through glutathione conjugation. It was also seen changes in the relative mass of the spleen and 
lungs of MTX rats. 
Conclusions:  SLM protects partially against MTX-induced hepatotoxicity.  
Keywords:  Hepatotoxicity, Hepato protection, Milk thistle, Silymarin, Rheumatoid arthritis. 
 
INTRODUCTION 
Methotrexate (MTX) is effective in the treatment of rheumatoid 
arthritis, decreasing its mortality [1, 2] and being considered the 
gold standard between disease modifying anti-rheumatic drugs [3]. 
Notwithstanding, rheumatic patients frequently use MTX 
chronically, exacerbating MTX-related undesirable effects and 
limiting therapy and life quality [4]. Patients exceeding doses of 20 
mg/week, and it is frequently reached in refractory or severe 
rheumatoid arthritis, present increased rates of toxic events[5]. One 
of the most relevant adverse effects related to MTX chronic 
administration is hepatotoxicity [4]. 
Silymarin (SLM) is extracted from milk thistle Silybum marianum 
and it is used as a phytotherapic drug to treat hepatic disorders such 
as jaundice, cirrhosis, and hepatitis due to its known hepato-
protective effect [6, 7]. SLM also presents antioxidant and anti-
inflammatory effects [8–10]. 
Considering that SLM is a promising compound to prevent MTX-
induced hepatotoxicity, the present study aimed to evaluate the 
protective effects of SLM against MTX-induced hepatic disturbances 
after a sub chronic oral administration using male Wistar rats as an 
experimental model. 
MATERIALS AND METHODS 
Chemicals 
MTX was purchased from Blausiegel, Brazil (Metrexato®) and SLM 
was obtained from Nycomed Pharma, Brazil (Legalon®
Animals  
, Sylibum 
marianum extract standardized to contain SLM 64 mg/5 ml). 5,5-
dithio-bis(2-nitrobenzoic acid) (DTNB), DPPH (1,1-diphenyl-2-
picrylhydrazyl) and malondyaldehyde were purchased from Sigma-
Aldrich, Brazil. All chemicals and reagents were of analytical grade. 
Adult male Wistar rats (8-week old, weighting 303±21g) were kept 
in individual cages in order to perform individual consumption 
analysis. Animals were acclimated for 1 week prior to the study. 
Food and water were provided ad libitum, animals were subjected to 
a 12 h dark/light cycle and experiments were approved by Ethical 
Committee on the use of animals from University of Passo Fundo 
(CEUA-UPF, protocol 018/2013). 
Treatment 
Animals were distributed into four groups (seven animals per 
group), and were treated by oral gavage, for four weeks:  control 
group (saline solution, daily), MTX group (MTX 900µg/kg, once a 
week and saline solution daily in order to allow the same 
manipulation and gavage stress conditions), SLM group (SLM 50 
mg/kg, daily), and MTX+SLM group (MTX 900µg/kg, once a week 
and SLM 50 mg/kg, daily). Administration volume was 5 ml/kg. MTX 
and SLM doses were defined through allomeric relationship in order 
to correlate with human doses. After four weeks, rats were 
euthanized under anesthesia with xylazin/ketamine (10 mg/kg and 
100 mg/kg, respectively) by diaphragm rupture. A necropsy was 
performed to all animals.  
Clinical evaluations 
During the experiment, daily clinical evaluations of all animals were 
performed. The parameters evaluated were piloerection, 
dehydration, haemorrhage and diarrhea, motor function (tone and 
movement coordination), breathing (rate and depth, gasping), 
mucosal color (pale, cyanotic), and clinical signals of abdominal pain. 
The individual weight and consumption of food and water were also 
recorded every day until the end of the study. 
Haematology 
Under anaesthesia, blood was collected by puncture of the cava vein 
using EDTA as anticoagulant. Collected blood was used from 
haematological analysis.  
Organ-specific toxicity:  relative organ mass and macroscopic 
analysis 
In the day of euthanasia, organs (liver, spleen, heart, kidneys, and 
lung) were excised, washed with phosphate-buffered saline solution 
(pH 7.4), dried and weighted to assess the relative mass (calculated 
as the percentage of the total body-weight) [11]. Macroscopic 
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evaluations were carefully performed in order to describe visible 
changes in the organ architecture.  
Tissue preparation for microscopic analysis 
Liver pieces of about five mm 3 were fixed in formaldehyde 10% for 
48 h and then dehydrated with graded ethanol. After dehydration 
steps, samples were fixed with xylene and included in paraffin 
blocks. Semi thin sections of three μm were cut and mounted in 
slides. After de waxed with xylene, tissue sections were stained with 
haematoxylin/eosin and analyzed under a light microscope coupled 
to a digital camera. 
Determinations on the hepatic tissue 
Liver samples were homogenized [1:4 (m/v)] in ice-cold phosphate-
buffered saline solution, pH 7.4, with an Ultra-Turrax homogenizer 
and centrifuged (3 000 g, 10 min) [11]. Aliquots of supernatant were 
taken to assess hepatic protein levels, lipid peroxidation, non-proteic 
thiols content, and total antioxidant capacity, as described below.  
Hepatic protein levels 
Hepatic protein levels were quantified through Bradford method [12]. 
Hepatic lipid peroxidation  
Hepatic lipid peroxidation was assessed through the thiobarbituric 
acid reactive species reaction [13]. The product of this reaction was 
quantified through spectrophotometry at 535 nm. Results were 
expressed as n mol/mg of protein. 
Non-proteic thiols content 
Non-proteic thiols were quantified as an indirect measure of 
intracellular glutathione content, as previously described [14]. 
Results were expressed as n mol/mg of protein. 
Total antioxidant capacity 
Total antioxidant capacity of the hepatic tissue was verified through 
the scavenging of DPPH free radical assay [15]. The absorbance was 
monitored spectrophotometrically at 517 nm. 
Statistical analysis  
Normality distribution was assessed through Shapiro-Wilk test. 
Statistical comparisons between groups that presented normal 
distribution were performed by repeated measures ANOVA followed 
by the Student Newman Keuls post hoc test (relative body weight 
gain and the consumptions of food and water) and Kruskal-Wallis 
followed by Dunn’s post hoc (relative organs mass and hepatic tissue 
determinations) was used to compare variables without normal 
distribution. Statistical analysis was performed using Graph Pad 
Prim, version 5.0. Significance was accepted at p values<0.05. 
RESULTS 
Lack of systemic toxicity 
During the study, all rats increased relative body-weight gain 
similarly between groups. Furthermore, it was not observed 
significant changes in food and water consumption or significant 
alterations in clinical evaluations or haematologic parameters, 
evidencing that doses employed did not elicit systemic toxicity and 
either haemato toxicity. 
Organ-target toxicity 
One rat treated with MTX presented macroscopic alterations in the 
liver and one rat from MTX+SLM group presented liver adhered to 
diaphragm. It was not observed any macroscopic change in liver 
from control or SLM groups. Possible hepatic changes were better 
elucidated by microscopy and results are presented in the fig. 1. 
It was shown a not significant decrease in the spleen relative mass 
from MTX treated rats in comparison with control animals. On the 
other hand, animals treated with SLM (alone or with MTX) 
presented significant increases in spleen relative mass compared to 
MTX group. This increase was not significant when compared to 
control group (fig. 2).  
It was not observed significant changes in relative mass of liver, 
kidneys and heart between groups (data not shown). Animals 
treated with MTX presented increases in the relative mass of lung. 
These changes were significant when comparing MTX group with 
the control group. The administration of SLM was not able to 
counteract these changes caused by MTX, as can be seen in the fig. 2. 
SLM protects liver against MTX-induced lipid peroxidation 
despite decreases in the non-proteic thiols content 
No significant changes were observed in hepatic protein levels and 
total antioxidant capacity between groups (data not shown). 
However, it was observed an increase in hepatic lipid peroxidation 
in MTX rats compared to control and the use of SLM with MTX was 
able to decrease this lipid peroxidation (fig. 3). Interestingly, 
MTX+SLM group presented decreases in the hepatic non-proteic 
thiol content when compared to control levels (fig. 4). 
 
Fig. 1: Optic microscopy from hepatic tissue alterations 
representative from each treatment group (400x). A) Control 
group, without changes. B) MTX group, presenting hydropic 
degeneration and isolated necrosis in hepatocytes. In detail, a 
fibrotic nodule is evidenced. C) SLM group, presenting cellular 
tumefaction. D) MTX+SLM group, presenting cellular 
tumefaction and isolated necrosis in hepatocytes 
 
 
Fig. 2: Relative mass of A) spleen and B) lung. Results are 
presented as means±standard deviation (N=seven rats per 
group). Statistical analysis was performed by Kruskal-Wallis 
test followed by Dunns post hoc test (*p<0.05 vs MTX;  **p<0.01 
vs MTX;  #p<0.05 vs control) 
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Fig. 3: Lipid peroxidation in liver evaluated through 
malondyaldehyde quantification. Results are presented as 
means±standard deviation (N=seven rats per group). Statistical 
analysis was performed by Kruskal-Wallis test followed by 
Dunns post hoc test (*
 
p<0.05 vs Control) 
 
Fig. 4: Hepatic non-proteic thiols content. Results are presented 
as means±standard deviation (N=seven rats per group). 
Statistical analysis was performed by Kruskal-Wallis test 
followed by Dunns. (*p<0.05vs Control) 
 
DISCUSSION 
The major finding of this work highlighted that the co-
administration of SLM and MTX prevents the hepatic lipid 
peroxidation elicited by MTX chronic administration. This effect, 
however, was not enough to revert histologic changes observed in 
liver tissue. 
MTX chronic treatment causes hepatic fibrosis and cirrhosis, 
normally seen in long administration schedules such as 2 to 10 
years, reaching about 20 to 50% of patients [16, 17]. A contributing 
factor for MTX-induced hepatotoxicity is the accumulation of MTX 
metabolites, namely polyglutamate, in the hepatic tissue, where they 
can be retained for months [5, 18]. In the present study, rats treated 
with MTX alone presented hydropic degeneration, a condition 
characterized by the beginning of functional impairment. In more 
susceptible animals, it was observed the aggravation of liver lesions 
evidenced by the presence of isolated necrosis, which was also 
observed in MTX+SLM livers. 
SLM is recognized as a hepato protective agent [6, 7], presenting 
promising results against hepatotoxicity observed during 
chemotherapy [19]. Animals treated with SLM alone presented 
cellular tumefaction. It is well known that SLM stabilizes the 
membrane of hepatocytes, preventing toxins from entering the cell 
through entero hepatic recirculation, regenerates liver by 
stimulating nucleolar polymerase A and increasing ribosomal 
protein synthesis [20]. Moreover, the described mechanism of action 
of SLM comprises a strong antioxidant and anti-inflammatory 
potential [20]. In this way, the histo pathological alterations 
observed in livers of SLM group possibly can be attributed to 
adaptive changes related to these effects. Furthermore, our results 
shown that SLM inhibits hepatic lipid peroxidation, high lighting the 
efficacy of SLM in protecting against membrane damage (fig. 3). 
Lipid peroxidation inhibition was also seen in vitro after incubation 
with SLM [9] corroborating the hypothesis that SLM protective 
effects are mediated through antioxidant effects upon lipids [9, 21]. 
However, besides SLM antioxidant properties, in the present work, 
this change was not accompanied by alterations in the hepatic total 
antioxidant capacity. Furthermore, herein was shown a decrease in 
the non-proteic thiols in MTX+SLM group when compared to control 
values (fig. 4). Non-proteic thiols are an indirect measure of reduced 
glutathione, a free radical scavenger related to the endogenous non-
enzymatic antioxidant system [22].  
The use of SLM is reported to maintain reduced glutathione 
homeostasis and, frequently, elevated glutathione levels are seen 
after treatment with SLM [21, 23]. However, with the present dose 
and regimen of administration, it was not possible to observe this 
effect. One could speculate in order to explain reduced non-proteic 
thiols levels in the MTX+SLM group that SLM favors detoxification 
process through glutathione conjugation with reactive species 
since SLM increases glutathione-transferase activity [23, 24], thus 
consuming more glutathione molecules and contributing to this 
result. 
MTX treatment is related to haematological disturbances such as 
decreased blood cell counts and megaloblastic anaemia, leukopenia, 
pancytopenia, and thrombocytopenia [25]. It is known that 
decreases in blood cells might influence in spleen relative mass since 
it is a lymphoid organ considered a reservoir of blood cells. In the 
present study, besides the absence of significant alterations in 
haematological parameters, animals treated with SLM presented 
increased spleen relative mass when compared to MTX group (fig. 
2). Immunosuppressive agents cause the reduction of the splenic 
white pulp by induction of cellular apoptosis and, consequently, 
reduce the size and relative mass of this organ [26]. Although not 
significant, MTX group showed a reduction in spleen compared to 
other groups. Thus, the anti-inflammatory effect of SLM might be 
also related to spleen protection. 
Another found was the increased relative mass of the lungs in the 
MTX group. Pulmonary alterations were frequently described in 
patients using MTX. MTX-induced lung disease is characterized as 
pneumonitis, bronchitis, and even fibrosis [27, 28]. 
In summary, the present work highlighted the occurrence of MTX-
induced organ-target toxicity since it was observed significant 
changes in lungs, spleen, and liver of MTX treated rats. Despite 
pulmonary and spleen observations, this work focused on hepatic 
disturbances since hepatotoxicity limits MTX chronic therapy. The 
main mechanism of MTX-induced hepatotoxicity in our model was 
lipid peroxidation and SLM administration reverted this effect 
without changing hepatic antioxidant capacity. Although, SLM 
administration did not counteract histologic changes induced by 
MTX, evidencing that SLM protection was partial in the present 
animal model and regimen of administrations. 
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